{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:37:11Z","timestamp":1792654631543,"version":"4.5.0"},"reference-count":120,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T00:00:00Z","timestamp":1554768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.00683","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T06:13:47Z","timestamp":1554790427000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":52,"title":["Exploitation of Neisseria meningitidis Group B OMV Vaccines Against N. gonorrhoeae to Inform the Development and Deployment of Effective Gonorrhea Vaccines"],"prefix":"10.3389","volume":"10","author":[{"given":"Helen","family":"Petousis-Harris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona J.","family":"Radcliff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,4,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis - implications for vaccine development and pathogenesis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1128\/IAI.01358-12","article-title":"Phase variation of PorA, a major outer membrane protein, mediates escape of bactericidal antibodies by Neisseria meningitidis","volume":"81","author":"Tauseef","year":"2013","journal-title":"Infect Immun."},{"key":"B3","doi-asserted-by":"publisher","first-page":"5955","DOI":"10.1128\/IAI.72.10.5955-5962.2004","article-title":"Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design","volume":"72","author":"Urwin","year":"2004","journal-title":"Infect Immun."},{"key":"B4","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1136\/adc.2009.180596","article-title":"Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers","volume":"96","author":"Jackson","year":"2011","journal-title":"Arch Dis Childhood."},{"key":"B5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jinf.2017.05.001","article-title":"Predicted vs observed effectiveness of outer membrane vesicle (OMV) vaccines against meningococcal serogroup B disease: systematic review","volume":"75","author":"Harder","year":"2017","journal-title":"J Infect."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","article-title":"Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway","volume":"338","author":"Bjune","year":"1991","journal-title":"Lancet."},{"key":"B7","first-page":"195","article-title":"Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba","volume":"14","author":"Sierra","year":"1991","journal-title":"NIPH Ann."},{"key":"B8","first-page":"53","article-title":"Mucosal approaches in neisseria vaccinology","volume":"18","author":"P\u00e9rez","year":"2009","journal-title":"Vacc Monitor."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1086\/522428","article-title":"A Framework for assessing immunological correlates of protection in vaccine trials","volume":"196","author":"Qin","year":"2007","journal-title":"J Infect Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/cid\/cis238","article-title":"Nomenclature for immune correlates of protection after vaccination","volume":"54","author":"Plotkin","year":"2012","journal-title":"Clin Infect Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(02)08679-8","article-title":"Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination","volume":"359","author":"Maiden","year":"2002","journal-title":"Lancet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(13)61612-8","article-title":"Effect of a serogroup A meningococcal conjugate vaccine (PsA\u2013TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study","volume":"383","author":"Daugla","year":"2014","journal-title":"Lancet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial","volume":"384","author":"Read","year":"2014","journal-title":"Lancet."},{"key":"B14","article-title":"Why stop MeNZB vaccination? Supporting evidence for withdrawal of epidemic strain outer membrane vesicle (OMV) vaccine in New Zealand","volume-title":"16th International Pathogenic Neisseria Conference","author":"Lennon","year":"2008"},{"key":"B15","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1128\/CVI.00529-09","article-title":"Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity","volume":"17","author":"Campbell","year":"2010","journal-title":"Clin Vacc Immunol."},{"key":"B16","first-page":"8","article-title":"Invasive meningococcal disease","volume":"19","author":"Perez","year":"2010","journal-title":"VaccinMonitor."},{"key":"B17","volume-title":"Annula Estadistico De Salud 2016","year":"2017"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.1128\/IAI.69.7.4502-4508.2001","article-title":"Immune response induction and new effector mechanisms possibly involved in protection conferred by the cuban anti-meningococcal BC vaccine","volume":"69","author":"P\u00e9rez","year":"2001","journal-title":"Infect Immun."},{"key":"B19","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1093\/cid\/cir007","article-title":"\u201cHerd Immunity\u201d: a rough guide","volume":"52","author":"Fine","year":"2011","journal-title":"Clin Infect Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/oxfordjournals.epirev.a036121","article-title":"Herd immunity: history, theory, practice","volume":"15","author":"Fine","year":"1993","journal-title":"Epidemiol Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/00007435-199411000-00010","article-title":"Estimating the basic reproductive rates of Neisseria gonorrhoeae and chlamydia trachomatis: the implications of acquired immunity","volume":"21","author":"Brunham","year":"1994","journal-title":"Sex Transm Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1086\/598983","article-title":"Modeling the impact of potential vaccines on epidemics of sexually transmitted chlamydia trachomatis infection","volume":"199","author":"Gray","year":"2009","journal-title":"J Infect Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1016\/j.vaccine.2015.07.015","article-title":"The potential impact of vaccination on the prevalence of gonorrhea","volume":"33","author":"Craig","year":"2015","journal-title":"Vaccine"},{"key":"B24","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.1016\/j.vaccine.2011.06.120","article-title":"Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand","volume":"29","author":"Arnold","year":"2011","journal-title":"Vaccine."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1001\/jama.281.16.1520","article-title":"Immunogenicity of 2 serogroup b outer-membrane protein meningococcal vaccines: a randomized controlled trial in chile","volume":"281","author":"Tappero","year":"1999","journal-title":"JAMA."},{"key":"B26","volume-title":"Sexually Transmitted Infections in New Zealand: Annual Surveillance Report 2014.","year":"2015"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/S0140-6736(17)31449-6","article-title":"Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study","volume":"390","author":"Petousis-Harris","year":"2017","journal-title":"Lancet."},{"key":"B28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/vaccines7010005","article-title":"Effectiveness of a group B outer membrane vesicle meningococcal vaccine in preventing hospitalization from gonorrhea in New Zealand: a retrospective cohort study","volume":"7","author":"Paynter","year":"2019","journal-title":"Vaccines."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1084\/jem.20020407","article-title":"NadA, a Novel vaccine candidate of Neisseria meningitidis","volume":"195","author":"Comanducci","year":"2002","journal-title":"J Exp Med."},{"key":"B30","article-title":"Vaccines for Neisseria Gonorrhoeae","year":"2017"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1061","article-title":"The serogroup B meningococcal vaccine Bexsero elicits antibodies to Neisseria gonorrhoeae","author":"Semchenko","year":"2018","journal-title":"Clin Infect Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"S734","DOI":"10.1093\/2Fofid\/2Fofx180.002","article-title":"Possible impact of wide-scale vaccination against serogroup B Neisseria meningitidis on gonorrhea incidence rates in one region of quebec, Canada","volume":"4","author":"Longtin","year":"2017","journal-title":"Open Forum Infect Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1136\/sti.79.2.124","article-title":"Gonorrhoea reinfection in heterosexual STD clinic attendees: longitudinal analysis of risks for first reinfection","volume":"79","author":"Mehta","year":"2003","journal-title":"Sex Transm Infect."},{"key":"B34","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/00007435-200110000-00001","article-title":"Experimental gonococcal urethritis and reinfection with homologous gonococci in male volunteers","volume":"28","author":"Schmidt","year":"2001","journal-title":"Sex Transm Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1172\/JCI114040","article-title":"Epidemiologic evidence for the development of serovar-specific immunity after gonococcal infection","volume":"83","author":"Plummer","year":"1989","journal-title":"J Clin Invest."},{"key":"B36","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1086\/314608","article-title":"Molecular typing of Neisseria gonorrhoeae causing repeated infections: evolution of porin during passage within a community","volume":"179","author":"Hobbs","year":"1999","journal-title":"J Infect Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1172\/JCI116190","article-title":"Antibody to Rmp (outer membrane protein 3) increases susceptibility to gonococcal infection","volume":"91","author":"Plummer","year":"1993","journal-title":"J Clin Invest."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1084\/jem.164.5.1735","article-title":"Immunoglobulin G antibodies directed against protein III block killing of serum-resistant Neisseria gonorrhoeae by immune serum","volume":"164","author":"Rice","year":"1986","journal-title":"J Exp Med."},{"key":"B39","first-page":"671","article-title":"Development of a gonorrhoea vaccine: prospects, strategies and tactics","volume":"62","author":"Gotschlich","year":"1984","journal-title":"Bull World Health Organ."},{"key":"B40","first-page":"29","article-title":"Gonococcal vaccine studies in Inuvik","volume":"65","author":"Greenberg","year":"1974","journal-title":"Can J Public Health."},{"key":"B41","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/0264-410X(91)90147-X","article-title":"Efficacy trial of a parenteral gonococcal pilus vaccine in men","volume":"9","author":"Boslego","year":"1991","journal-title":"Vaccine."},{"key":"B42","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1128\/CMR.2.Suppl.S74","article-title":"Gonococcal vaccines","volume":"2","author":"Tramont","year":"1989","journal-title":"Clin Microbiol Rev."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1093\/infdis\/174.6.1223","article-title":"Immunogenicity of Neisseria gonorrhoeae lipooligosaccharide epitope 2C7, widely expressed in vivo with no immunochemical similarity to human glycosphingolipids","volume":"174","author":"Gulati","year":"1996","journal-title":"J Infect Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e1003559","DOI":"10.1371\/journal.ppat.1003559","article-title":"Immunization against a saccharide epitope accelerates clearance of experimental gonococcal infection","volume":"9","author":"Gulati","year":"2013","journal-title":"PLoS Pathog."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1038\/mi.2017.11","article-title":"Experimental vaccine induces Th1-driven immune responses and resistance to Neisseria gonorrhoeae infection in a murine model","volume":"10","author":"Liu","year":"2017","journal-title":"Mucosal Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1086\/315801","article-title":"Intranasal immunization with gonococcal outer membrane preparations reduces the duration of vaginal colonization of mice by Neisseria gonorrhoeae","volume":"182","author":"Plante","year":"2000","journal-title":"J Infect Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"7558","DOI":"10.1128\/IAI.73.11.7558-7568.2005","article-title":"Comparison of immune responses to gonococcal PorB delivered as outer membrane vesicles, recombinant protein, or Venezuelan equine encephalitis virus replicon particles","volume":"73","author":"Zhu","year":"2005","journal-title":"Infect Immun."},{"key":"B48","doi-asserted-by":"publisher","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci USA."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","article-title":"Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1002\/pmic.200500821","article-title":"Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98\/254","volume":"6","author":"Vipond","year":"2006","journal-title":"Proteomics."},{"key":"B52","doi-asserted-by":"publisher","first-page":"B3","DOI":"10.1016\/j.vaccine.2009.04.071","article-title":"Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis","volume":"27","author":"Holst","year":"2009","journal-title":"Vaccine."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.vaccine.2013.12.070","article-title":"Immuno-proteomic analysis of human immune responses to experimental Neisseria meningitidis outer membrane vesicle vaccines identifies potential cross-reactive antigens","volume":"32","author":"Williams","year":"2014","journal-title":"Vaccine."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1074\/mcp.M113.029538","article-title":"Quantitative proteomics of the Neisseria gonorrhoeae cell envelope and membrane vesicles for the discovery of potential therapeutic targets","volume":"13","author":"Zielke","year":"2014","journal-title":"Mol Cell Proteom."},{"key":"B55","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.1128\/IAI.67.11.5699-5708.1999","article-title":"Experimental gonococcal genital tract infection and opacity protein expression in estradiol-treated mice","volume":"67","author":"Jerse","year":"1999","journal-title":"Infect Immun."},{"key":"B56","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1128\/IAI.05702-11","article-title":"Defining the roles of human carcinoembryonic antigen-related cellular adhesion molecules during neutrophil responses to Neisseria gonorrhoeae","volume":"80","author":"Sarantis","year":"2012","journal-title":"Infect Immun."},{"key":"B57","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1574-6976.2010.00260.x","article-title":"Opa proteins and CEACAMs: pathways of immune engagement for pathogenic Neisseria","volume":"35","author":"Sadarangani","year":"2011","journal-title":"FEMS Microbiol Rev."},{"key":"B58","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1086\/515372","article-title":"Cytokine and antibody responses in women infected with Neisseria gonorrhoeae: effects of concomitant infections","volume":"178","author":"Hedges","year":"1998","journal-title":"J Infect Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/infdis\/172.1.186","article-title":"Inflammatory cytokines produced in response to experimental human gonorrhea","volume":"172","author":"Ramsey","year":"1995","journal-title":"J Infect Dis."},{"key":"B60","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/mi.2009.139","article-title":"Critical role of Th17 responses in a murine model of Neisseria gonorrhoeae genital infection","volume":"3","author":"Feinen","year":"2010","journal-title":"Mucosal Immunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/mi.2012.12","article-title":"Neisseria gonorrhoeae selectively suppresses the development of Th1 and Th2 cells, and enhances Th17 cell responses, through TGF-beta-dependent mechanisms","volume":"5","author":"Liu","year":"2012","journal-title":"Mucosal Immunol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/mi.2013.36","article-title":"Suppression of host adaptive immune responses by Neisseria gonorrhoeae: role of interleukin 10 and type 1 regulatory T cells","volume":"7","author":"Liu","year":"2014","journal-title":"Mucosal Immunol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e00095","DOI":"10.1128\/mBio.00095-11","article-title":"Diversion of the immune response to Neisseria gonorrhoeae from Th17 to Th1\/Th2 by treatment with anti-transforming growth factor beta antibody generates immunological memory and protective immunity","volume":"2","author":"Liu","year":"2011","journal-title":"mBio."},{"key":"B64","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S1286-4579(02)01585","article-title":"Humoral immune responses to microbial infections in the genital tract","volume":"4","author":"Russell","year":"2002","journal-title":"Microbes Infect Institut Pasteur."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1080\/21645515.2015.1114195","article-title":"Induction of mucosal immunity through systemic immunization: Phantom or reality?","volume":"12","author":"Su","year":"2016","journal-title":"Hum Vaccin Immunother."},{"key":"B66","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1128\/CVI.00214-16","article-title":"Parenteral vaccination can be an effective means of inducing protective mucosal responses","volume":"23","author":"Clements","year":"2016","journal-title":"Clin Vaccine Immunol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1002\/ijc.25887","article-title":"Long-term persistence of systemic and mucosal immune response to HPV-16\/18 AS04-adjuvanted vaccine in preteen\/adolescent girls and young women","volume":"129","author":"Petaja","year":"2011","journal-title":"Int J Cancer."},{"key":"B68","doi-asserted-by":"publisher","first-page":"5899","DOI":"10.1016\/j.vaccine.2008.08.062","article-title":"MeNZB vaccine and epidemic control: when do you stop vaccinating?","volume":"26","author":"Loring","year":"2008","journal-title":"Vaccine."},{"key":"B69","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1128\/IAI.00466-06","article-title":"Comparison and correlation of Neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac","volume":"74","author":"Findlow","year":"2006","journal-title":"Infect Immun."},{"key":"B70","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1086\/590669","article-title":"Mucosal immunity in healthy adults after parenteral vaccination with outer-membrane vesicles from Neisseria meningitidis serogroup B","volume":"198","author":"Davenport","year":"2008","journal-title":"J Infect Dis."},{"key":"B71","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1017\/S0950268805004097","article-title":"Influence of age and carriage status on salivary IgA to Neisseria meningitidis","volume":"133","author":"Horton","year":"2005","journal-title":"Epidemiol Infect."},{"key":"B72","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nri3837","article-title":"Immune modulation by bacterial outer membrane vesicles","volume":"15","author":"Kaparakis-Liaskos","year":"2015","journal-title":"Nat Rev Immunol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.vaccine.2014.01.011","article-title":"Quantification by LC-MS(E) of outer membrane vesicle proteins of the Bexsero(R) vaccine","volume":"32","author":"Tani","year":"2014","journal-title":"Vaccine."},{"key":"B74","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/mi.2017.70","article-title":"Adjuvant selection regulates gut migration and phenotypic diversity of antigen-specific CD4(+) T cells following parenteral immunization","volume":"11","author":"Frederick","year":"2018","journal-title":"Mucosal Immunol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1600-065X.2010.00971.x","article-title":"Immunogenomics and systems biology of vaccines","volume":"239","author":"Buonaguro","year":"2011","journal-title":"Immunol Rev."},{"key":"B76","doi-asserted-by":"publisher","first-page":"e11835","DOI":"10.1371\/journal.pone.0011835","article-title":"Genome sequencing reveals widespread virulence gene exchange among human Neisseria species","volume":"5","author":"Marri","year":"2010","journal-title":"PLoS ONE."},{"key":"B77","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1574-695X.2000.tb01419.x","article-title":"Antigenic cross-reactivity between outer membrane proteins of Neisseria meningitidis and commensal Neisseria species","volume":"27","author":"Troncoso","year":"2000","journal-title":"FEMS Immunol Med Microbiol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1080\/21645515.2017.1381810","article-title":"Impact of meningococcal group B OMV vaccines, beyond their brief","volume":"14","author":"Petousis-Harris","year":"2018","journal-title":"Hum Vaccin Immunother."},{"key":"B79","doi-asserted-by":"publisher","first-page":"e00163","DOI":"10.1128\/mBio.00163-13","article-title":"Conservation of meningococcal antigens in the genus Neisseria","volume":"4","author":"Muzzi","year":"2013","journal-title":"mBio."},{"key":"B80","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/j.1600-0463.2012.02903.x","article-title":"Novel meningococcal 4CMenB vaccine antigens - prevalence and polymorphisms of the encoding genes in Neisseria gonorrhoeae","volume":"120","author":"Hadad","year":"2012","journal-title":"APMIS."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.vaccine.2005.09.043","article-title":"Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control","volume":"24","author":"Thornton","year":"2006","journal-title":"Vaccine."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1128\/CVI.00167-07","article-title":"Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens","volume":"14","author":"Hosking","year":"2007","journal-title":"Clin Vaccine Immunol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1016\/j.vaccine.2007.01.023","article-title":"Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand","volume":"25","author":"Oster","year":"2007","journal-title":"Vaccine."},{"key":"B84","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","article-title":"Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease","volume":"21","author":"Holst","year":"2003","journal-title":"Vaccine."},{"key":"B85","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2013serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine."},{"key":"B86","doi-asserted-by":"publisher","first-page":"B112","DOI":"10.1016\/j.vaccine.2009.04.065","article-title":"Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease","volume":"27","author":"Frasch","year":"2009","journal-title":"Vaccine."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1128\/CVI.05245-11","article-title":"Neisseria gonorrhoeae NspA induces specific bactericidal and opsonic antibodies in mice","volume":"18","author":"Li","year":"2011","journal-title":"Clin Vaccine Immunol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/IAI.00898-16","article-title":"MetQ of Neisseria gonorrhoeae is a surface-expressed antigen that elicits bactericidal and functional blocking antibodies","volume":"85","author":"Semchenko","year":"2017","journal-title":"Infect Immun."},{"key":"B89","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/infdis\/130.3.240","article-title":"Cross-reactivity of Neisseria gonorrhoeae and Neisseria meningitidis and the nature of antigens involved in the bactericidal reaction","volume":"130","author":"Tramont","year":"1974","journal-title":"J Infect Dis."},{"key":"B90","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1128\/CMR.2.Suppl.S112","article-title":"Molecular basis for serum resistance in Neisseria gonorrhoeae","volume":"2","author":"Rice","year":"1989","journal-title":"Clin Microbiol Rev."},{"key":"B91","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1128\/IAI.60.1.39-43.1992","article-title":"Gonococcal lipooligosaccharide sialylation prevents complement-dependent killing by immune sera","volume":"60","author":"Wetzler","year":"1992","journal-title":"Infect Immun."},{"key":"B92","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1084\/jem.187.5.743","article-title":"A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae","volume":"187","author":"Ram","year":"1998","journal-title":"J Exp Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"5063","DOI":"10.4049\/jimmunol.1103748","article-title":"The relative roles of factor H binding protein, neisserial surface protein A, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococci","volume":"188","author":"Lewis","year":"2012","journal-title":"J Immunol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.femsim.2004.05.010","article-title":"Retinoic acid treated HL60 cells express CEACAM1 (CD66a) and phagocytose Neisseria gonorrhoeae","volume":"42","author":"Pantelic","year":"2004","journal-title":"FEMS Immunol Med Microbiol."},{"key":"B95","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1128\/IAI.56.6.1625-1632.1988","article-title":"Model for invasion of human tissue culture cells by Neisseria gonorrhoeae","volume":"56","author":"Shaw","year":"1988","journal-title":"Infect Immun."},{"key":"B96","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1128\/IAI.67.3.1149-1156.1999","article-title":"Invasion of human mucosal epithelial cells by Neisseria gonorrhoeae upregulates expression of intercellular adhesion molecule 1 (ICAM-1)","volume":"67","author":"Jarvis","year":"1999","journal-title":"Infect Immun."},{"key":"B97","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1046\/j.1365-2958.2000.01694.x","article-title":"Interaction of primary human endometrial cells with Neisseria gonorrhoeae expressing green fluorescent protein","volume":"35","author":"Christodoulides","year":"2000","journal-title":"Mol Microbiol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1586\/14789450.2014.938640","article-title":"Neisseria proteomics for antigen discovery and vaccine development","volume":"11","author":"Christodoulides","year":"2014","journal-title":"Exp Rev Proteom."},{"key":"B99","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/978-1-61779-346-2_20","article-title":"Analysis of the immune response to Neisseria meningitidis using a proteomics approach","volume":"799","author":"Williams","year":"2012","journal-title":"Methods Mol Biol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1128\/CVI.00666-15","article-title":"Cellular immune responses in humans induced by two serogroup B meningococcal outer membrane vesicle vaccines given separately and in combination","volume":"23","author":"Oftung","year":"2016","journal-title":"Clin Vaccine Immunol."},{"key":"B101","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1128\/IAI.65.12.5184-5190.1997","article-title":"Human B- and T-cell responses after immunization with a hexavalent PorA meningococcal outer membrane vesicle vaccine","volume":"65","author":"van der Voort","year":"1997","journal-title":"Infect Immun."},{"key":"B102","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3201\/eid2202.150369","article-title":"Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England","volume":"22","author":"Ladhani","year":"2016","journal-title":"Emerg Infect Dis."},{"key":"B103","doi-asserted-by":"publisher","first-page":"5470","DOI":"10.1016\/j.vaccine.2017.07.056","article-title":"Emerging clinical experience with vaccines against group B meningococcal disease","volume":"36","author":"Wilkins","year":"2017","journal-title":"Vaccine"},{"key":"B104","doi-asserted-by":"publisher","first-page":"e020988","DOI":"10.1136\/bmjopen-2017-020988","article-title":"B Part of it protocol: a cluster randomised controlled trial to assess the impact of 4CMenB vaccine on pharyngeal carriage of Neisseria meningitidis in adolescents","volume":"8","author":"Marshall","year":"2018","journal-title":"BMJ Open."},{"key":"B105","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.vaccine.2014.01.081","article-title":"Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007\u20132012","volume":"32","author":"Larson","year":"2014","journal-title":"Vaccine."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.vaccine.2009.12.022","article-title":"A postmodern Pandora's box: anti-vaccination misinformation on the internet","volume":"28","author":"Kata","year":"2010","journal-title":"Vaccine."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.2105\/2FAJPH.2018.304567T","article-title":"Weaponized health communication: twitter bots and Russian trolls amplify the vaccine debate","volume":"108","author":"Broniatowski","year":"2018","journal-title":"Am J Public Health."},{"key":"B108","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41562-018-0331-6","article-title":"Politics and public trust shape vaccine risk perceptions","volume":"2","author":"Larson","year":"2018","journal-title":"Nat Hum Behav."},{"key":"B109","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1586\/14760584.2015.964212","article-title":"Vaccine hesitancy, vaccine refusal and the anti-vaccine movement: influence, impact and implications","volume":"14","author":"Dube","year":"2015","journal-title":"Expert Rev Vacc."},{"key":"B110","doi-asserted-by":"publisher","first-page":"k1771","DOI":"10.1136\/bmj.k1771","article-title":"European countries are urged to carry out catch-up campaigns as measles outbreaks continue","volume":"361","author":"Wise","year":"2018","journal-title":"BMJ."},{"key":"B111","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/canjclin.57.1.7","article-title":"American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors","volume":"57","author":"Saslow","year":"2007","journal-title":"CA Cancer J Clin."},{"key":"B112","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jama.2009.1179","article-title":"Marketing HPV vaccine: implications for adolescent health and medical professionalism","volume":"302","author":"Rothman","year":"2009","journal-title":"JAMA."},{"key":"B113","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1503\/cmaj.070944","article-title":"Human papillomavirus, vaccines and women's health: questions and cautions","volume":"177","author":"Lippman","year":"2007","journal-title":"Can Med Assoc J."},{"key":"B114","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/bmj.39164.510127.AD","article-title":"Life saving treatment or giant experiment?","volume":"334","author":"Coombes","year":"2007","journal-title":"BMJ."},{"key":"B115","doi-asserted-by":"publisher","first-page":"F139","DOI":"10.1016\/j.vaccine.2012.05.039","article-title":"Human papillomavirus vaccine introduction\u2013the first five years","volume":"30","author":"Markowitz","year":"2012","journal-title":"Vaccine."},{"key":"B116","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13584-017-0153-4","article-title":"On the implications of desexualizing vaccines against sexually transmitted diseases: health policy challenges in a multicultural society","volume":"6","author":"Velan","year":"2017","journal-title":"Israel J Health Policy Res."},{"key":"B117","doi-asserted-by":"publisher","first-page":"262","DOI":"10.5694\/mja16.00958","article-title":"HPV vaccine coverage is increasing in Australia","volume":"206","author":"Brotherton","year":"2017","journal-title":"Med J Austr."},{"key":"B118","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1016\/j.vaccine.2017.04.060","article-title":"Mapping information exposure on social media to explain differences in HPV vaccine coverage in the United States","volume":"35","author":"Dunn","year":"2017","journal-title":"Vaccine."},{"key":"B119","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/cncr.30647","article-title":"An alert to Latin America: current human papillomavirus vaccination trends highlight key barriers to successful implementation","volume":"123","author":"Nogueira-Rodrigues","year":"2017","journal-title":"Cancer."},{"key":"B120","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ygyno.2017.04.004","article-title":"HPV vaccines \u2013 a review of the first decade","volume":"146","author":"Harper","year":"2017","journal-title":"Gynecol Oncol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00683\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T20:20:58Z","timestamp":1607199658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00683\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,9]]},"references-count":120,"alternative-id":["10.3389\/fimmu.2019.00683"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.00683","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,9]]},"article-number":"683"}}